ストックスクリーナーアプリを入手
5.325
2.40%
0.125
アフターアワーズ：
5.25
-0.075
-1.41%
前日終値:
$5.20
開ける：
$5.2699
24時間の取引高:
21,246
Relative Volume:
0.78
時価総額：
$38.12M
収益：
$85,000
当期純損益:
$-22.16M
株価収益率:
-0.1414
EPS:
-37.672
ネットキャッシュフロー:
$-6.29M
1週間 パフォーマンス:
+12.11%
1か月 パフォーマンス:
-10.13%
6か月 パフォーマンス:
-48.15%
1年 パフォーマンス:
-60.54%
1日の値動き範囲:
$4.75
$5.40
1週間の範囲:
$4.19
$5.40
52週間の値動き範囲:
$3.85
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
5.325 | 37.23M | 85,000 | -22.16M | -6.29M | -37.67 |
ABT
Abbott Laboratories
|
110.37 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.68 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.60 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.43 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.81 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-05 | 開始されました | Ascendiant Capital Markets | Buy |
| 2018-06-28 | 開始されました | Maxim Group | Buy |
Pavmed Inc (PAVM) 最新ニュース
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Q2 2026 Earnings Call Transcript - MarketBeat
PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan
PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative
PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine
PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test - Bitget
P&F Products & Features GmbH Announces Acquisition of AVVie GmbH - AOL.com
Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria - Stock Titan
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Morningstar
Academic Orthopaedic Consortium Launches POST™, the First National Digital Platform Connecting MedTech, Pharma, and Academic Orthopaedic Departments - AOL.com
Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings - Stock Titan
Weekly Recap: Q2 2026 earnings call and EsoGuard/EsoCheck sales - TradingView
PAVmed Inc. (PAVM) Climbs 4.42% to $5.24 as Bullish Momentum BuildsGap Up Stocks - dars.gov.et
PAVmed CEO to update operations; CFO to discuss Q2 financial results Aug. 14 - Stock Titan
PAVmed to Host Business Update Conference Call on August 14 - Intellectia AI
PAVMED Q1 2026 Earnings: EPS Shock Sinks Shares as Revenue Remains UnreportedEarnings Surprise Stocks - dars.gov.et
PAVmed Inc (PAVM) Cash Flow - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PAVmed Inc (PAVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pavmed Inc (PAVM) 財務データ
収益
当期純利益
現金流量
EPS
2.43%
大文字化:
|
ボリューム (24 時間):